A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia

Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML

(2018) Andreas T. Björklund et al.   CLINICAL CANCER RESEARCH

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

(2015) S S Kenderian et al.   LEUKEMIA

Natural killer cell therapy in children with relapsed leukemia

(2015) Jeffrey E. Rubnitz et al.   PEDIATRIC BLOOD & CANCER

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation

(2014) N. N. Shah et al.   BLOOD

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

(2014) Alan S. Gamis et al.   JOURNAL OF CLINICAL ONCOLOGY

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

(2011) A. Curti et al.   BLOOD

NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia

(2010) Jeffrey E. Rubnitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

(2009) H. Fujisaki et al.   CANCER RESEARCH

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity

(2008) D. Pende et al.   BLOOD